BTG3 and autoimmune disease: Fifty-five (45.5%) case participants and 75 (40.8%) control participants had previous laboratory testing for inflammatory markers of autoimmune diseases, including antinuclear antibodies (ANA), anti-dsDNA, cyclic citrullinated peptide (CCP), rheumatoid factor (RF), SSA-SSB antibodies, complement, anticardiolipin antibodies (ACA), and antineutrophil cytoplasmic antibodies (ANCA).